Unlocking Africa's vaccine Independence: The critical role of technology transfer and intellectual property.

The COVID-19 pandemic exposed Africa's profound dependency on external vaccine suppliers, with the continent producing less than 1% of global vaccines and hosting only 1.1% of clinical trials. Despite emerging initiatives, most African facilities remain limited to downstream fill-and-finish operations, while full vaccine antigen manufacturing capacity is largely absent. This perspective paper examines the critical role of Technology Transfer (TT) and Intellectual Property (IP) access in achieving Africa's vaccine independence. Effective TT must extend beyond documentation to include unspoken know-how, on-site mentorship, regulatory dossiers, and supply-chain integration. Simultaneously, pragmatic IP frameworks through voluntary licensing, patent pooling, and time-bound waivers are essential to enable lawful and sustainable local production. Drawing lessons from mature European and U.S. ecosystems, the paper highlights the need for regional manufacturing clusters, harmonized regulatory systems under the African Medicines Agency (AMA), and African pooled procurement mechanisms to ensure market viability. Persistent challenges such fragmented regulation, supply-chain fragility, limited skilled human capital, and uncertain financing continue to constrain progress and highlight the imperative for political commitment to be operationalized through sustained structural investments. Africa's vaccine sovereignty will depend on aligning TT with IP reform, regional cooperation, and predictable market assurance, transforming the continent from a dependent recipient into a resilient and globally competitive vaccine producer.